Want to see TSE:SONA full AI Analyst Report?
Top Page
Sona Nanotech Inc
(SONA)
Select Model
Select Model
Rating:40Underperform
Price Target:
C$0.27
▼(-33.50% Downside)
Action:Downgraded
Date:07/09/26
The score is primarily constrained by weak financial performance: no reported revenue, persistent losses, continued cash burn, and a recent shift to negative equity that increases balance-sheet and financing risk. Technicals also lean bearish with the stock trading below major moving averages and negative MACD. Valuation provides little support due to negative earnings and no stated dividend yield.
Positive Factors
Proprietary gold nanorod IP and diagnostics focus
Sona’s proprietary gold nanorod technology and explicit focus on diagnostics and life-science workflows create a durable product-led moat. If commercialized, specialty labeling materials can generate recurring B2B demand, licensing opportunities, and sticky customer relationships in research and diagnostic supply chains.
Negative Factors
No reported revenue
The absence of reported revenue means the company has not yet demonstrated commercial product-market fit. Without sales, the business cannot scale margins, prove demand, or self-fund operations, increasing reliance on external capital and raising execution risk for transitioning from R&D to commercial supplier.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary gold nanorod IP and diagnostics focus
Sona’s proprietary gold nanorod technology and explicit focus on diagnostics and life-science workflows create a durable product-led moat. If commercialized, specialty labeling materials can generate recurring B2B demand, licensing opportunities, and sticky customer relationships in research and diagnostic supply chains.
Read all positive factors
Sona Nanotech Inc (SONA) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$32.03M
Dividend YieldN/A
Average Volume (3M)124.26K
Price to Earnings (P/E)―
Beta (1Y)0.76
Revenue GrowthN/A
EPS Growth14.18%
CountryCA
Employees8
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.02
Shares Outstanding114,375,250
10 Day Avg. Volume87,178
30 Day Avg. Volume124,263
Financial Highlights & Ratios
PEG Ratio-2.89
Price to Book (P/B)-1.80K
Price to Sales (P/S)0.00
P/FCF Ratio-35.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)N/A
Sona Nanotech Inc Business Overview & Revenue Model
Company Description
Based in Halifax, Canada, Sona Nanotech Inc. is a life sciences company focused on nanotechnology. It develops and commercializes gold nanorod solutions primarily for diagnostic applications. Their product portfolio includes the Nanotech COVID-19 ...
How the Company Makes Money
null...
Sona Nanotech Inc Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Jan 2026 | Jan 2025 | Jan 2024 | Jan 2023 | Jan 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -720.00K | -720.00K | -733.98K | -457.00K | -60.32K | -65.59K |
| EBITDA | -2.22M | -2.72M | -2.00M | -2.02M | -2.34M | -10.38M |
| Net Income | -2.75M | -3.25M | -2.70M | -2.50M | -2.36M | -10.77M |
Balance Sheet | ||||||
| Total Assets | 752.35K | 1.33M | 3.75M | 2.75M | 520.77K | 1.52M |
| Cash, Cash Equivalents and Short-Term Investments | 52.76K | 125.95K | 1.86M | 115.38K | 164.42K | 1.20M |
| Total Debt | 328.87K | 307.74K | 394.67K | 527.68K | 608.47K | 1.34M |
| Total Liabilities | 1.47M | 1.37M | 1.24M | 1.59M | 1.03M | 2.75M |
| Stockholders Equity | -714.07K | -38.78K | 2.51M | 1.16M | -507.86K | -1.22M |
Cash Flow | ||||||
| Free Cash Flow | -1.26M | -1.96M | -1.96M | -1.26M | -1.81M | -3.81M |
| Operating Cash Flow | -1.26M | -1.96M | -1.96M | -1.26M | -1.81M | -3.81M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 14.64K | 0.00 | 0.00 |
| Financing Cash Flow | 585.94K | 228.43K | 3.70M | 1.20M | 778.00 | 4.89M |
Sona Nanotech Inc Technical Analysis
Positive
0.40
Price Trends
0.30
Positive
0.32
Negative
0.42
Negative
Market Momentum
>-0.01
Negative
52.85
Neutral
29.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:SONA, the sentiment is Positive. The current price of 0.4 is above the 20-day moving average (MA) of 0.29, above the 50-day MA of 0.30, and below the 200-day MA of 0.42, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.85 is Neutral, neither overbought nor oversold. The STOCH value of 29.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:SONA.
Sona Nanotech Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | C$68.89M | -123.91 | ― | ― | 19.84% | 52.94% | |
48 Neutral | C$57.80M | -34.01 | ― | ― | -40.80% | 22.49% | |
46 Neutral | C$45.61M | -21.67 | ― | ― | 45.72% | 35.82% | |
40 Underperform | C$32.03M | -12.40 | -434.25% | ― | ― | 14.18% |
* Healthcare Sector Average
TSE:SONA
Sona Nanotech Inc
0.30
-0.25
-45.45%
TSE:BUX
BioMark Diagnostics
0.55
0.20
57.14%
TSE:EBM
Eastwood Bio-Medical Canada
1.00
0.52
106.19%
TSE:SZLS.H
StageZero Life Sciences Ltd
0.04
0.00
0.00%
TSE:MIR
Medmira
0.07
>-0.01
-13.33%
TSE:ZYUS
ZYUS Life Sciences
0.50
-0.22
-30.56%
Sona Nanotech Inc Corporate Events
Business Operations and StrategyExecutive/Board Changes
Sona Nanotech Adds Leading Oncologists to Advisory Board as It Advances Cancer Therapy
Positive
Apr 16, 2026
Sona Nanotech has strengthened its scientific advisory board with the appointment of two prominent oncologists, melanoma specialist Dr. Michael Smylie and head and neck cancer surgeon Dr. Jonathan Trites. Management believes their expertise in imm...
Business Operations and Strategy
Sona Nanotech Study Supports Tumor-Priming Potential of Targeted Hyperthermia Cancer Therapy
Positive
Apr 13, 2026
Sona Nanotech reported follow-up histology data from its first-in-human early feasibility study of its Targeted Hyperthermia Therapy in advanced melanoma patients who had failed standard immunotherapy. Analysis of post-treatment tumor tissues show...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.